Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
Top Cited Papers
- 31 January 2007
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 132 (1), 52-65
- https://doi.org/10.1053/j.gastro.2006.11.041
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Anti-TNF-alpha therapy in ankylosing spondylitisCytokine, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaquesBritish Journal of Dermatology, 2005
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- SUCCESSFUL TREATMENT WITH ADALIMUMAB IN INFLIXIMAB‐RESISTANT CROHN's DISEASEJournal of Gastroenterology and Hepatology, 2005
- Severe anaphylactic reaction to infliximabEuropean Journal of Gastroenterology & Hepatology, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseThe New England Journal of Medicine, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999